Evidence map›Paper›PMID 29176872›Full record

ArticlePloS one2017

Para-hydroxyphenylpyruvate inhibits the pro-inflammatory stimulation of macrophage preventing LPS-mediated nitro-oxidative unbalance and immunometabolic shift.

Rosella Scrima, Marta Menga, Consiglia Pacelli, Francesca Agriesti, Olga Cela, Claudia Piccoli, Antonella Cotoia, Alessandra De Gregorio, Julia V Gefter, Gilda Cinnella and 1 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rosella ScrimaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Marta MengaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Consiglia PacelliDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Francesca AgriestiLaboratory of Pre-Clinical and Translational Research, IRCCS CROB, Rionero in Vulture, Potenza, Italy.
Olga CelaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Claudia PiccoliDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Antonella CotoiaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Alessandra De GregorioDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Julia V GefterDepartment of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, United States of America.
Gilda CinnellaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Nazzareno CapitanioDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.ORCID http://orcid.org/0000-0001-9285-051X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting metabolism is emerging as a promising therapeutic strategy for modulation of the immune response in human diseases. In the presented study we used the lipopolysaccharide (LPS)-mediated activation of RAW 264.7 macrophage-like cell line as a model to investigate changes in the metabolic phenotype and to test the effect of p-hydroxyphenylpyruvate (pHPP) on it. pHPP is an intermediate of the PHE/TYR catabolic pathway, selected as analogue of the ethyl pyruvate (EP), which proved to exhibit antioxidant and anti-inflammatory activities. The results obtained show that LPS-priming of RAW 264.7 cell line to the activated M1 state resulted in up-regulation of the inducible nitric oxide synthase (iNOS) expression and consequently of NO production and in release of the pro-inflammatory cytokine IL-6. All these effects were prevented dose dependently by mM concentrations of pHPP more efficiently than EP. Respirometric and metabolic flux analysis of LPS-treated RAW 264.7 cells unveiled a marked metabolic shift consisting in downregulation of the mitochondrial oxidative phosphorylation and upregulation of aerobic glycolysis respectively. The observed respiratory failure in LPS-treated cells was accompanied with inhibition of the respiratory chain complexes I and IV and enhanced production of reactive oxygen species. Inhibition of the respiratory activity was also observed following incubation of human neonatal fibroblasts (NHDF-neo) with sera from septic patients. pHPP prevented all the observed metabolic alteration caused by LPS on RAW 264.7 or by septic sera on NHDF-neo. Moreover, we provide evidence that pHPP is an efficient reductant of cytochrome c. On the basis of the presented results a working model, linking pathogen-associated molecular patterns (PAMPs)-mediated immune response to mitochondrial oxidative metabolism, is put forward along with suggestions for its therapeutic control.

Indexed as

AnimalsAnti-Inflammatory AgentsCell RespirationFibroblastsHumansHypoxia-Inducible Factor 1, alpha SubunitInflammationInterleukin-6LipopolysaccharidesMacrophagesMetabolic Flux AnalysisMiceMitochondriaModels, BiologicalNitratesNitric Oxide4-hydroxyphenylpyruvic acidAnti-Inflammatory Agentsethyl pyruvateHypoxia-Inducible Factor 1, alpha SubunitInterleukin-6LipopolysaccharidesNitratesNitric OxideNitric Oxide Synthase Type IINitritesPeroxidesPhenylpyruvic AcidsPyruvates

Identifiers

PMID29176872
PMCPMC5703549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.